Royalty Pharma plc (NASDAQ:RPRX) currently has a daily average trading volume of 5.11M but it saw 8948609 shares traded in last market. With a market cap of 19.83B USD, the company’s current market price of $35.27 came rising about 3.58 while comparing to the previous closing price of $34.05. In past 52 weeks, the stock remained buoying in the range of price level as high as $34.31 and as low as $24.05. In the recent trading on the day, stock has struck highest price mark of $34.14 while lowest mark touched by it was $35.37.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Morgan Stanley which initiated the stock as “Overweight” in its note to investors issued on May 16, 2025, recommending a price target of $51 for it. UBS downgraded its recommendation for the stock as a “Neutral” from “Buy” on June 03, 2024 while assigning a price target of $28. UBS issued its recommendations for the stock as it resumed the price target for the stock is $47.
Over the week, RPRX’s stock price is moving 4.50% up while it is 7.46% when we observe its performance for the past one month. Year-to-date it is 38.26% up and over the past year, the stock is showing an upside performance of 28.77%.
The company is expected to be releasing its next quarterly report on 2025-May-07, for which analysts forecasted an EPS of 1.05 while estimate for next year EPS is 4.42. In next quarter, company is expected to be making quarterly sales of $764.1M as analysts are expecting the sales for current fiscal year at $3.08B and seeing the company making $3.27B in sales next year. Moreover, analysts are in estimates of $750.06M for current-quarter revenue.
Currently, Royalty Pharma plc’s total number of outstanding shares is 425.59M with 8.92% of that held by the insiders while 79.18% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 8.21% and return on equity (ROE) at 16.57%. It has a price to earnings ratio (P/E ratio) of 14.38 while having a 7.02 of forward P/E ratio. Stock’s beta reads 0.48. Stock has a price to book (P/B) ratio of 2.24 while price to sale or P/S ratio amounts to 8.76. Its return on asset (ROA) is 6.48% on average.
